Algeta inks research agreement with Genzyme

As per the agreement, Genzyme expects to provide access to a novel and proprietary tumor-targeting antibody, and Algeta will provide access to its Thorium platform to attach the alpha emitting payload thorium-227.

Algeta executive vice president and chief technology officer Thomas Ramdahl said they are delighted to work with Genzyme on this important new approach to cancer treatment, which combines their cancer-killing payload thorium-227 with the novel antibody’s own target specificity and tumor cell degradation properties.

"Algeta has previously demonstrated the promise of our alpha-emitter thorium-227 as a payload and we now look forward to applying our Thorium platform to this novel antibody," Ramdahl said.